TAK 187: structure in first source; ergosterol biosynthesis inhibitor with possible usage against Trypanosoma [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 479655 |
| CHEMBL ID | 54333 |
| SCHEMBL ID | 1456168 |
| MeSH ID | M0274584 |
| Synonym |
|---|
| unii-08vsm3612t |
| 08vsm3612t , |
| 2-[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1,2,4-triazol-1-yl)propyl]-4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-1,2,4-triazol-3-one |
| tak-187 |
| 155432-64-7 |
| 2-(2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl)-4-(4-(2,2,3,3-tetrafluoropropoxy)phenyl)-3(2h,4h)-1,2,4-triazolone |
| tak 187 |
| 2-[(2r,3r)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-1,2,4-triazol-3-one |
| CHEMBL54333 |
| SCHEMBL1456168 |
| 2-[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-3(2h,4h)-1,2,4-triazolone |
| DTXSID20935209 |
| 2-[3-(2,4-difluorophenyl)-3-hydroxy-4-(1h-1,2,4-triazol-1-yl)butan-2-yl]-4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-2,4-dihydro-3h-1,2,4-triazol-3-one |
| 2-((1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy)-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl)-4-(4-(2,2,3,3-tetrafluoropropoxy)phenyl)-3-(2h,4h)-1,2,4-triazolone |
| 3h-1,2,4-triazol-3-one, 2-((1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl)-2,4-dihydro-4-(4-(2,2,3,3-tetrafluoropropoxy)phenyl)- |
| 3h-1,2,4-triazol-3-one, 2-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-2,4-dihydro-4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]- |
| AKOS040749607 |
| 3h-1,2,4-triazol-3-one, 2-[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-2,4-dihydro-4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]- |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Based upon its therapeutic efficacy and long half-life in the rabbit model, TAK-187 should be investigated for intermittent dosing in treatment or suppression of cryptococcal infections in humans." | ( In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans. De Almeida, GM; Dodge, RK; Okonogi, K; Perfect, JR; Schell, WA, 1998) | 0.3 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID119046 | The compound was tested in vivo for anti-candida activity in mice model 2(dose: 1 mg/kg, untreated group).; not tested | 1998 | Journal of medicinal chemistry, May-21, Volume: 41, Issue:11 | New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. |
| AID73614 | In vitro antifungal activity against 6 filamentous fungi | 1998 | Journal of medicinal chemistry, May-21, Volume: 41, Issue:11 | New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. |
| AID118899 | In vivo antifungal activity against murine candidosis model after peroral administration with 1 mg/kg for 5 days.(percent protection for 100% mortality with untreated group); not tested | 1998 | Journal of medicinal chemistry, May-21, Volume: 41, Issue:11 | New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol. |
| AID119048 | The compound was tested in vivo for anti-candida activity in mice model 2(dose :1 mg/kg,fluconazole-treated group); not tested | 1998 | Journal of medicinal chemistry, May-21, Volume: 41, Issue:11 | New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. |
| AID118897 | In vivo antifungal activity against murine candidosis model after peroral administration with 1 mg/kg for 5 days.(percent protection for 100% mortality with fluconazole-treated group.); not tested | 1998 | Journal of medicinal chemistry, May-21, Volume: 41, Issue:11 | New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol. |
| AID73613 | The compound was tested in vitro for antifungal activity against 6 filamentous fungi. | 1998 | Journal of medicinal chemistry, May-21, Volume: 41, Issue:11 | New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol. |
| AID118765 | In vivo antifungal activity against murine candidosis model after peroral administration with 0.5 mg/kg at various time intervals. (percent protection for 100% mortality with untreated group) | 1998 | Journal of medicinal chemistry, May-21, Volume: 41, Issue:11 | New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol. |
| AID220225 | The compound was tested in vitro for antifungal activity against 10 yeasts. | 1998 | Journal of medicinal chemistry, May-21, Volume: 41, Issue:11 | New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol. |
| AID220226 | In vitro for antifungal activity against 10 yeasts | 1998 | Journal of medicinal chemistry, May-21, Volume: 41, Issue:11 | New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. |
| AID118760 | In vivo antifungal activity against murine candidosis model after peroral administration with 0.5 mg/kg at various time intervals. (percent protection for 100% mortality with fluconazole-treated group.) | 1998 | Journal of medicinal chemistry, May-21, Volume: 41, Issue:11 | New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol. |
| AID119042 | Tested in vivo for anti-candida activity in mice model 1 (dose: 0.5 mg/kg, untreated group). | 1998 | Journal of medicinal chemistry, May-21, Volume: 41, Issue:11 | New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. |
| AID119038 | Tested in vivo for anti-candida activity in mice model 1 (dose:0.5 mg/kg, fluconazole-treated group) | 1998 | Journal of medicinal chemistry, May-21, Volume: 41, Issue:11 | New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.08) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||